Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure

Boisot, Saskia; Beede, Jennifer; Isakson, Susan R.; Chiu, Albert; Clopton, Paul; Januzzi, James L.; Maisel, Alan S.; Fitzgerald, Robert L.

doi:10.1016/j.cardfail.2008.06.415

Cited by 195 publications

(154 citation statements)

References 25 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…The circulating biomarker, soluble ST2 (sST2) has been shown to be a powerful independent prognosticator for patients with acute myocardial infarction (AMI)1, 2 as well as acute decompensated3, 4 and chronic5, 6, 7, 8, 9 HF. sST2, a member of the interleukin (IL)‐1 receptor‐like family of proteins, is released in response to myocyte stretch, and functions as a decoy receptor, neutralizing its ligand, IL‐33.…”

Section: Introductionmentioning

confidence: 99%

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Parikh

Seliger

Christenson

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundSoluble ST2 (sST2), a marker of myocyte stretch and fibrosis, has prognostic value in many cardiovascular diseases. We hypothesized that sST2 levels are associated with incident heart failure (HF), including subtypes of preserved (HFpEF) and reduced (HFrEF) ejection fraction, and cardiovascular death.Methods and ResultsBaseline serum sST2 was measured in 3915 older, community‐dwelling subjects from the Cardiovascular Health Study without prevalent HF. sST2 levels were associated with older age, male sex, black race, traditional cardiovascular risk factors, other biomarkers of inflammation, cardiac stretch, myocardial injury, and fibrosis, and abnormal echocardiographic parameters. In longitudinal analysis, greater sST2 was associated with a higher risk of incident HF and cardiovascular death; however, in multivariate models adjusting for other cardiac risk factors and the cardiac‐specific biomarker, N‐terminal pro–type B natriuretic peptide, these associations were attenuated. In these models, an sST2 level above the US Food and Drug Administration–approved cut‐off value (>35 ng/mL) was significantly associated with incident HF (hazard ratio [HR], 1.20; 95% CI, 1.02–1.43) and cardiovascular death (HR, 1.21; 95% CI, 1.02–1.44), and greater sST2 was continuously associated with cardiovascular death (per 1‐ln increment: HR, 1.24; 95% CI, 1.02–1.50). sST2 was not associated with the HF subtypes of HFpEF and HFrEF in adjusted analysis. Addition of sST2 to existing risk models of HF and cardiovascular death modestly improved discrimination and reclassification into a higher risk.ConclusionsThe predictive value of sST2 for HF of all subtypes and cardiovascular death is modest in an elderly population despite strong cross‐sectional associations with risk factors and underlying cardiac pathology.

show abstract

Section: Introductionmentioning

confidence: 99%

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Parikh

Seliger

Christenson

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…19 However, in our study, we measured sST2 levels only at presentation and proved associations with the unfavorable course of HF independently of NT-proBNP levels.…”

mentioning

confidence: 54%

Single sST2 protein measurement predicts adverse outcomes at 1‑year follow‑up in patients with chronic heart failure

Sobczak¹,

Wojtczak-Soska²,

Ciurus³

et al. 2014

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…Even in the asymptomatic patients (Wang et al 2013), if the ST2 serum levels are higher than the cutoff 35 ng/ml, it means there is significant cardiac damage Dieplinger 2013, Januzzi 2013). We can monitor ST2 serum level to predict disease occurrence ) and make treatment plans as early as possible (Boisot et al 2008, Manzano-Fernández et al 2012). In addition ACCF/AHA has proposed the 2013 Guideline for the Management of Heart Failure that includes ST2 in the recommendations (Yancy et al 2013).…”

Section: Backgroundsmentioning

confidence: 99%

Clinical roles of soluble ST2 for the outcomes of cardiac valve operations

Chen¹

2016

RIO

View full text Add to dashboard Cite

Executive summarySoluble ST2 is a novel cardiac biomarker that reflects cardiac injury and the response to treatment. Previous studies showed that ST2 has less confounding and more specific than NT-proBNP. ACCF/AHA has proposed 2013 Guidelines for the Management of Heart Failure that includes ST2 in the recommendations. In the research proposal, we will assess the clinical role of serum ST2 level in cardiac non-coronary valve surgical patients.We will recruit 70 patients who undergo cardiac non-coronary valve operations. Serum levels of ST2 and NT-proBNP and troponin-T will be measured at preoperative baseline, postoperative 24 hours, and postoperative 5 to 10 days in the routine blood sampling. The endpoints include hospital mortality, all-cause mortality, unexpected ICU return, MACE, time to extubation, and total length of stay. We will also collect various preoperative, operative, and postoperative variables, such as EuroScore-II. Their relationships will be analyzed.We expect to demonstrate the superior role of ST2 to NT-proBNP and other variables in risk stratification and outcome prediction and assessment in our cohort. ‡, §

show abstract

Serial Sampling of ST2 Predicts 90-Day Mortality Following Destabilized Heart Failure

Cited by 195 publications

References 25 publications

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Single sST2 protein measurement predicts adverse outcomes at 1‑year follow‑up in patients with chronic heart failure

Clinical roles of soluble ST2 for the outcomes of cardiac valve operations

Contact Info

Product

Resources

About